SYGNIS AG signs distribution agreement for Switzerland
LABGENE Scientific to sell next generation sequencing and single cell analysis applications
SYGNIS AG announced that it has signed a distribution agreement with LABGENE Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Switzerland.
Under the terms of the agreement, SYGNIS has granted LABGENE Scientific the rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in Switzerland. These product lines cover the Company’s TruePrime™ products for primer-free whole genome amplification as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.